Categories
Change Password!
Reset Password!
As compared with conventional treatment, Guluronic acid 500 mg twice
day is safe, well-tolerated and portrays
superior efficacy for treatment of RA.
According
to a study issued in 'Immunopharmacology and Immunotoxicology', the
effectiveness of guluronic acid in combination with conventional therapy has
been highlighted with more desirable safety profile as compared to
conventional-treated patients as explained from routine rheumatology clinical
practice data. Shahin Khadem Azarian and researchers assessed the safety,
efficacy and tolerability of guluronic acid (G2013) for the treatment of
rheumatoid arthritis patients who had an inappropriate response to conventional
drugs.
This
randomized, 12-week clinical trial comprised of two treatment arms: guluronic
acid (G2013) and conventional treatment. The diagnosed RA patients as per the
ACR/European League against Rheumatism 2010 classification criteria with active
disease at baseline who had an inadequate response to conventional therapy were
included in this study. Guluronic acid, 500 mg, was administered twice daily
for 12 weeks. Then, the patients were followed up for safety and
efficacy.
The mean changes in guluronic acid and control groups were −7.54 and −2.5 for
the tender joint count; −23.18 and −1.81 for patient global assessment; −7.59
and −3.59 for the swollen joint count; −30 and −0.9 for physician global
assessment; −14.45 and −1.45 for erythrocyte sedimentation rate. Guluronic acid depicted more significant
improvements than those with conventional drugs. All in all, around15.3% of
guluronic acid-treated patients and 69.2% of conventional-treated patients experienced
adverse events (AEs).
"Guluronic acid therapy could be a suitable choice
for RA disease management", noted the study researchers.
Immunopharmacology and Immunotoxicology
A randomized clinical trial for the assessment of the efficacy and safety of guluronic acid (G2013) in patients with rheumatoid arthritis
Shahin Khadem Azarian et al.
Comments (0)